Soleno Therapeutics Sued Over Alleged DCCR Safety Misrepresentations in Class Action Lawsuit

Soleno Therapeutics Faces Class Action Lawsuit Over Alleged Misrepresentation of DCCR Safety

Soleno Therapeutics, Inc. (NASDAQ: SLNO) finds itself embroiled in a class action lawsuit instigated by Rosen Law Firm, targeting purchasers of its common stock from March 26, 2025, to November 4, 2025. This legal action raises serious allegations regarding the company’s communications about the safety and effectiveness of its lead drug candidate, diazoxide choline extended-release tablets (DCCR). The lawsuit claims that Soleno made false and misleading statements, particularly with respect to potential safety issues associated with DCCR, such as excessive fluid retention—a concern that may impair the drug's commercial viability.

The lawsuit specifically challenges Soleno's representation of DCCR during its Phase 3 clinical trials, asserting that the company downplayed critical safety concerns that could pose serious risks to patients. According to the plaintiffs, these misrepresentations artificially inflated the stock's market value, misleading investors about the true nature of DCCR's safety profile. As a result, those who bought shares within the specified timeframe may have been disadvantaged, creating an impetus for the class action suit. Interested parties may join the lawsuit, which operates on a contingency fee basis, meaning that individuals can seek compensation without upfront legal costs.

Rosen Law Firm, noted for its substantial experience in securities class actions, emphasizes the importance of selecting experienced legal counsel for such cases. The firm has built a strong reputation, highlighted by its record-breaking settlements and accolades in the field. With the deadline to serve as lead plaintiff set for May 5, 2026, potential claimants are encouraged to act promptly. This lawsuit marks a pivotal moment for Soleno Therapeutics as it seeks to navigate the repercussions of these allegations while continuing its commitment to developing innovative treatments in the biotech sector.

In response to the lawsuit, Soleno has yet to publicly address the concerns raised regarding DCCR. The implications of the allegations are especially critical as DCCR aims to provide therapeutic benefits for patients with Prader-Willi syndrome, a rare genetic disorder that severely affects appetite regulation and metabolism. The market’s perception of DCCR’s safety could significantly impact its future commercialization efforts and overall corporate reputation.

As the lawsuit proceeds, stakeholders will closely monitor how Soleno Therapeutics manages its communications and next steps in addressing these serious allegations. With New standards of transparency becoming paramount in the biotech industry, the outcome of this case may set a precedent regarding accountability and corporate governance in drug development.